Sector News

Givaudan chairman, CFO to retire

October 10, 2016
Life sciences

Givaudan’s chairman and finance chief will stand down next year, the Swiss fragrance and flavor maker said on Monday while reporting slower like-for-like sales growth in the third quarter of 2016.

Geneva-based Givaudan, which makes fragrances for perfumes and toothpaste and flavors for food and beverages, posted third-quarter sales of 1.184 billion Swiss francs ($1.21 billion).

Like-for-like sales growth from July to September was 3.1 percent, half the 6.2 percent growth rate seen in the first half and short of a forecast for 3.4 percent in a Reuters poll of seven analysts.

Analysts had expected a slowdown in sales growth due to a strong year-ago performance and an erosion of forex-driven price increases which had boosted its Latin America business.

“However, the reversal of the U.S. dollar pricing proved to be more acute than we had anticipated,” Kepler Cheuvreux analyst Aymeric Poulain, who has a “hold” rating on the stock, wrote in a note to investors.

“This is likely to remain a top-line growth drag over the next few quarters and could cap earnings estimates for now, while putting pressure on the higher end of consensus.”

Givaudan shares fell 1.7 percent in early trading, lagging a 0.5 percent fall in the Swiss blue-chip index .SSMI.

Givaudan confirmed its mid-term targets of 4-5 percent sales growth and a free cash flow of 12-17 percent of sales.

Third-quarter sales at its fragrances division, which creates scents for Dior and Bottega Veneta, rose 3.4 percent to 567 million francs, while sales at the flavors division, whose products are used by food groups like Nestle and Danone, were up 2.9 percent at 617 million francs.

Givaudan has been seeking to compensate for a weaker trading environment in western Europe and North America by winning new contracts from food companies in faster-growing regions like South America and Asia.

Givaudan said Chairman Juerg Witmer will retire in March 2017 with Calvin Grieder proposed for election as his replacement.

Chief Financial Officer Matthias Waehren will also retire at the end of 2016 and Tom Hallam, head of group controlling and business development, will take over as CFO from Jan. 1, Givaudan said.

By Joshua Franklin

Source: Reuters

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend